NAT1 and breast carcinoma: Seven different drugs were investigated in four breast cancer cell lines – triple negative MDA-MB-231 cells, estrogen receptor positive T-47D cells, NAT1 deficient MDA-MB-231 cells and NAT1 deficient T47D cells.